The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

ViroPharma To Participate In The JMP Securities Healthcare Conference

Tuesday, July 03, 2012

ViroPharma To Participate In The JMP Securities Healthcare Conference12:00 EDT Tuesday, July 03, 2012EXTON, Pa., July 3, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Colin Broom, MD, vice president and chief scientific officer of ViroPharma, will present at the 2012 JMP Securities Healthcare Conference at 11:00 A.M. ET on Thursday, July 12, 2012.  The conference is being held at the Peninsula Hotel in New York City.ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.About ViroPharma IncorporatedViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, Friedreich's Ataxia, and adrenal insufficiency; and recurrent C. difficile infection (CDI). Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures and C. difficile-associated diarrhea (CDAD); for full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com. ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.SOURCE ViroPharma IncorporatedFor further information: Robert A. Doody Jr., Assistant Director, Investor Relations, +1-610-321-6290